Efavirenz | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Efavirenz
US Patents

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

With Fermion, start the journey of your innovative API.

Contact Supplier

Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Efavirenz

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

40 API Suppliers, 28 USDMF, 13 EU WC, 2 KDMF, 22 NDC API, 19 Listed Suppliers, $ API Reference Price

40 API Suppliers
28 USDMF
13 EU WC
2 KDMF
22 NDC API
19 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

4 Intermediates Suppliers

4 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

196 FDF Dossiers, 59 FDA Orange Book, 40 Europe, 11 Canada, 67 South Africa, 19 Listed Dossiers

196 FDF Dossiers
59 FDA Orange Book
40 Europe
11 Canada
67 South Africa
19 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 400MG;300MG;300MG, CAPSULE;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 600MG, TABLET;ORAL - 600MG;200MG;300MG

TABLET;ORAL - 400MG;300MG;300MG
CAPSULE;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE;ORAL - 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
CAPSULE;ORAL - 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 600MG
TABLET;ORAL - 600MG;200MG;300MG

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 2 Seqens, 8 DKSH, 4 Faran Shimi Pharmaceutical, 10 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 3 Actylis, 1 Aeon Procare, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 14 BASF, 10 Corel Pharma Chem, 6 DFE Pharma, 1 Finar, 7 Gangwal Chemicals, 7 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 31 Kerry, 3 Kima Chemical, 6 Lonza Capsugel, 10 Microlex e.U, 2 Nomisma Healthcare, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 4 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 12 Roquette, 7 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 12 Sigachi Industries, 2 The Dow Chemical Company, 4 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

52 Coating Systems & Additives, 48 Fillers, Diluents & Binders, 29 Controlled & Modified Release, 25 Disintegrants & Superdisintegrants, 22 Direct Compression, 21 Thickeners and Stabilizers, 17 Lubricants & Glidants, 17 Granulation, 11 Co-Processed Excipients, 10 Topical, 9 Empty Capsules, 8 Film Formers & Plasticizers, 6 Taste Masking, 5 Parenteral, 5 API Stability Enhancers, 5 Coloring Agents, 5 Solubilizers, 4 Vegetarian Capsules, 4 Emulsifying Agents, 3 Chewable & Orodispersible Aids, 3 Rheology Modifiers, 1 Surfactant & Foaming Agents

52 Coating Systems & Additives
48 Fillers, Diluents & Binders
29 Controlled & Modified Release
25 Disintegrants & Superdisintegrants
22 Direct Compression
21 Thickeners and Stabilizers
17 Lubricants & Glidants
17 Granulation
11 Co-Processed Excipients
10 Topical
9 Empty Capsules
8 Film Formers & Plasticizers
6 Taste Masking
5 Parenteral
5 API Stability Enhancers
5 Coloring Agents
5 Solubilizers
4 Vegetarian Capsules
4 Emulsifying Agents
3 Chewable & Orodispersible Aids
3 Rheology Modifiers
1 Surfactant & Foaming Agents

DIGITAL CONTENT

3 DATA COMPILATION #PharmaFlow, 55 NEWS #PharmaBuzz

3 DATA COMPILATION #PharmaFlow
55 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 24 Finished Drug Prices, 15 Annual Reports

3 US Medicaid Prescriptions
24 Finished Drug Prices
15 Annual Reports

MARKET PLACE

8 APIs, 5 FDF Dossiers

8 APIs
5 FDF Dossiers

PATENTS & EXCLUSIVITIES

10 US Patents, 10 Health Canada Patents

10 US Patents
10 Health Canada Patents

REF. STANDARDS & IMPURITIES

5 USP, 5 Others

5 USP
5 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ API Ref.Price (USD/KG) : 94 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

10 All

01 10GILEAD SCIENCES

filter Patent Number Reset all filters

10 All

01 28592397

02 18598185

03 18716264

04 29018192

05 19457036

06 29545414

07 19744181

filter API Patent Reset all filters

10 All

01 10Blank

filter FDF Patent Reset all filters

10 All

01 8Y

02 2Blank

filter Expiration Date Reset all filters

10 All

01 52024-01-13

02 42026-06-13

03 12029-04-28

Product Main Page

01

GILEAD SCIENCES

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Antibody Engineering

Not Confirmed

GILEAD SCIENCES

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-01-13

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

US Patent Number : 8592397

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 21937

Patent Use Code : U-1170

Delist Requested :

Patent Use Description : TREATMENT OF HIV-1 INF...

Patent Expiration Date : 2024-01-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

GILEAD SCIENCES

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Antibody Engineering

Not Confirmed

GILEAD SCIENCES

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-01-13

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

US Patent Number : 8592397

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 21937

Patent Use Code : U-750

Delist Requested :

Patent Use Description : TREATMENT OF HIV-1 INF...

Patent Expiration Date : 2024-01-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

GILEAD SCIENCES

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Antibody Engineering

Not Confirmed

GILEAD SCIENCES

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-01-13

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

US Patent Number : 8716264

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 21937

Patent Use Code : U-257

Delist Requested :

Patent Use Description : TREATMENT OF HIV INFEC...

Patent Expiration Date : 2024-01-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

GILEAD SCIENCES

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Antibody Engineering

Not Confirmed

GILEAD SCIENCES

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-06-13

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

US Patent Number : 9018192

Drug Substance Claim :

Drug Product Claim :

Application Number : 21937

Patent Use Code : U-750

Delist Requested :

Patent Use Description : TREATMENT OF HIV-1 INF...

Patent Expiration Date : 2026-06-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

GILEAD SCIENCES

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Antibody Engineering

Not Confirmed

GILEAD SCIENCES

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-01-13

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

US Patent Number : 9744181

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 21937

Patent Use Code : U-257

Delist Requested :

Patent Use Description : TREATMENT OF HIV INFEC...

Patent Expiration Date : 2024-01-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

GILEAD SCIENCES

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Antibody Engineering

Not Confirmed

GILEAD SCIENCES

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-06-13

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

US Patent Number : 9545414

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 21937

Patent Use Code : U-1170

Delist Requested :

Patent Use Description : TREATMENT OF HIV-1 INF...

Patent Expiration Date : 2026-06-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

GILEAD SCIENCES

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Antibody Engineering

Not Confirmed

GILEAD SCIENCES

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-06-13

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

US Patent Number : 9545414

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 21937

Patent Use Code : U-750

Delist Requested :

Patent Use Description : TREATMENT OF HIV-1 INF...

Patent Expiration Date : 2026-06-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

GILEAD SCIENCES

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Antibody Engineering

Not Confirmed

GILEAD SCIENCES

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2024-01-13

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

US Patent Number : 9457036

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 21937

Patent Use Code : U-257

Delist Requested :

Patent Use Description : TREATMENT OF HIV INFEC...

Patent Expiration Date : 2024-01-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

GILEAD SCIENCES

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Antibody Engineering

Not Confirmed

GILEAD SCIENCES

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-06-13

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

US Patent Number : 9018192

Drug Substance Claim :

Drug Product Claim :

Application Number : 21937

Patent Use Code : U-1170

Delist Requested :

Patent Use Description : TREATMENT OF HIV-1 INF...

Patent Expiration Date : 2026-06-13

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

GILEAD SCIENCES

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

Antibody Engineering

Not Confirmed

GILEAD SCIENCES

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2029-04-28

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

US Patent Number : 8598185

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 21937

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2029-04-28

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?